Amarin Technologies S.A. ("AMARIN" or "The Company") is engaged in the development of innovative pharmaceutical products using its proprietary topical and transdermal drug delivery technology and know-how to offer improved formulations of established drugs. The Company is located in Buenos Aires, Argentina.

Amarin’s main product is a transdermal delivery system of Fentanyl (Fentanyl TDS), which is being commercialized by several companies in Germany, France, Greece, Taiwan, Hungary and Argentine, under different brand names (Fentadolon®, Dolforin®, Talnur®, among others). Fentanyl TDS is finalizing the Mutual Recognition Procedure in Europe and it is under registration phase in some Latinamerican countries, other than Argentina, by Sandoz and Mega Pharma. A new version of the Fentanyl TDS for the US market is under development.

Amarin pipeline also includes:

-  Selegiline TDS (pre-Registration in USA)

-  Diclofenac 1% TDS (Pharmaceutical Development)

-  Diclofenac 1% Gel (Pharmaceutical Development)

-  Rivastigmine TDS (Pharmaceutical Development)

Other products developed by Amarin Technologies, which are comercialized by licensee companies are:

- 5% diclofenac gel (OXA® Gel Plus, Artren® Hipergel): Argentina, Perú.

- 1% Testosterone gel (Androlone® Gel; Zandrova®): Argentina, India, Korea.

- 0.06% Estradiol Gel (Trial® Gel): Argentina.

- Estradiol TDS (Trial Sat®): Argentina.

AMARIN's research and evelopment capabilities allow the company to carry out all steps of a new product development process. An experienced team coordinates all of the company's research, project planning and product development programs. The company performs an exhaustive background analysis of the selected agent for a transdermal formulation before beginning the developments. It includes the evaluation of the patent status by an IP team specialized in pharmaceutical matters. AMARIN possesses formulation and analytical laboratories, which follow GLP guidelines.

AMARIN designs and performs pre-clinical and clinical studies following GLP and GCP guidelines in order to evaluate bioavailability/bioequivalence and the efficacy/safety of the products under development. Clinical trials are performed in qualified hospitals and private Health Centers.

AMARIN does not have a marketing force and pursues a strategy of out-licensing its products to corporate partners. Nowadays, the company's business opportunities are, amongst others, focused in three main strategies: (a) Finding new partners for the existing projects or, (b) Developing new products on request or, (c) Developing early stage projects to be offered to selected candidates.

Among the existing commercial relationships, we can disclose those which cover our products with Merck KGaA (Germany), Zydus Cadila (India), Sandoz (Austria), Genericon Pharma Gesellschaft m.b.H. (Austria), Helm Pharmaceuticals (Germany), Laboratorios Beta S.A. (Argentina), Eurofarma (Brazil), Unimed (Korea), Ranbaxy (India), Mega Pharma (Uruguay), TAD Pharma GmbH (Germany), Gedeon RichterLtd (Hungary), Esparma GmbH (Germany), Biogaran (France), , Mibe GmbH (Germany), Krewel Meuselbach GmbH (Germany), Generis Farmaceutica S.A.(Portugal), (Kwizda Pharma GmbH (Austria), Laboratorios Cinfa S.A.(Spain), Laboratorios Normon S.A. (Spain), Kern Pharma S.A. (Spain), Heumann Pharma GmbH (Germany), Adcock Ingram Healthcare (Pty) Ltd. (South Africa), Algol Pharma OY (Finland), Gry Pharma GmbH (Germany), Drossapharma AG (Switzerland),P N Gerolymatos S.A. (Greece), Demos S.A. (Greece), Aliud Pharma GmbH (Germany), BioPro Pharmaceuticals Inc (USA), Teva Santè (France).